BDNF polymorphisms are associated with schizophrenia onset and positive symptoms

Schizophrenia Research

Volumn 170, Issue 1, 2016, Pages 41-47

  Zhang, Xiang Yang ^a,b   Chen, Da Chun ^a   Tan, Yun Long ^a   Tan, Shu ping ^a   Luo, Xingguang ^c   Zuo, Lingjun ^c   Soares, Jair C ^b  

^a PEKING UNIVERSITY   (China)

^b University of Texas Harris County Psychiatric Center   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Association; BDNF; Haplotype; Polymorphism; Schizophrenia; Symptoms

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; BDNF GENE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAN CHINESE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84947340904     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.11.009     Document Type: Article

References (56)

1. Adachi N., Numakawa T., Richards M., Nakajima S., Kunugi H. New insight in expression, transport, and secretion of brain-derived neurotrophic factor: implications in brain-related diseases. World J. Biol. Chem. 2014, 5(4):409-428.
2. Ahmed A.O., Mantini A.M., Fridberg D.J., Buckley P.F. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. Psychiatry Res. 2015, 226(1):1-13.
3. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389(6653):856-860.
4. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr. Res. 2007, 91(1-3):1-5.
5. Chang H.A., Lu R.B., Shy M.J., Chang C.C., Lee M.S., Huang S.Y. Brain-derived neurotrophic factor Val66Met polymorphism: association with psychopathological symptoms of schizophrenia?. J. Neuropsychiatr. Clin. Neurosci. 2009, 21(1):30-37.
6. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology 2009, 207(3):375-380.
7. Chen Q.Y., Chen Q., Feng G.Y., Wan C.L., Lindpaintner K., Wang L.J., et al. Association between the brain-derived neurotrophic factor (BDNF) gene and schizophrenia in the Chinese population. Neurosci. Lett. 2006, 397:285-290.
8. Collins A.L., Kim Y., Sklar P., International Schizophrenia Consortium, O'Donovan M.C., Sullivan P.F. Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results. Psychol. Med. 2012, 42(3):607-616.
9. Dong E., Dzitoyeva S.G., Matrisciano F., Tueting P., Grayson D.R., Guidotti A. Brain-derived neurotrophic factor epigenetic modifications associated with schizophrenia-like phenotype induced by prenatal stress in mice. Biol. Psychiatry 2015, 77(6):589-596.
10. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
11. Fernandes B.S., Steiner J., Berk M., Molendijk M.L., Gonzalez-Pinto A., Turck C.W., et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol. Psychiatry 2014, [Epub ahead of print]. 10.1038/mp.2014.117.
12. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
13. Gauderman W.J. Sample size requirements for association studies of gene-gene interaction. Am. J. Epidemiol. 2002, 155:478-484.
14. Giusti-Rodríguez P., Sullivan P.F. The genomics of schizophrenia: update and implications. J. Clin. Invest. 2013, 123:4557-4563.
15. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol. Psychiatry 2011, 16(9):960-972.
16. Ikegame T., Bundo M., Murata Y., Kasai K., Kato T., Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. J. Hum. Genet. 2013, 58(7):434-438.
17. Jönsson E.G., Edman-Ahlbom B., Sillén A., Gunnar A., Kulle B., Frigessi A., et al. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30(5):924-933.
18. Kawashima K., Ikeda M., Kishi T., Kitajima T., Yamanouchi Y., Kinoshita Y., et al. BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophr. Res. 2009, 112(1-3):72-79.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
20. Kheirollahi M., Kazemi E., Ashouri S. Brain-derived neurotrophic factor gene Val66Met polymorphism and risk of schizophrenia: a meta-analysis of case-control studies. Cell Mol. Neurobiol. 2015, [Epub ahead of print].
21. Kochunov P., Hong L.E. 2014. Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. Schizophr. Bull. 2014, 40:721-728.
22. Kwon H.J., Ha M., Jin H.J., Hyun J.K., Shim S.H., Paik K.C., Park W.S., Lim M.H. Association between BDNF gene polymorphisms and attention deficit hyperactivity disorder in Korean children. Genet. Test Mol. Biomarkers 2015, 19(7):366-371.
23. Lally J., MacCabe J.H. Antipsychotic medication in schizophrenia: a review. Br. Med. Bull. 2015, 114(1):169-179.
24. Lee W.C. Detecting population stratification using a panel of single nucleotide polymorphisms. Int. J. Epidemiol. 2003, 32:1120.
25. Lencz T., Lipsky R.H., DeRosse P., Burdick K.E., Kane J.M., Malhotra A.K. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br. J. Psychiatry 2009, 194(4):313-318.
26. Li W., Zhou N., Yu Q., Li X., Yu Y., Sun S., et al. Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013, 162B(6):538-545.
27. Licinio J., Dong C., Wong M.L. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry 2009, 66(5):488-497.
28. Lohmueller K.E., Pearce C.L., Pike M., Lander E.S., Hirschhorn J. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 2003, 33:177-182.
29. Mitchelmore C., Gede L. Brain derived neurotrophic factor: epigenetic regulation in psychiatric disorders. Brain Res. 2014, 1586:162-172.
30. Naoe Y., Shinkai T., Hori H., Fukunaka Y., Utsunomiya K., Sakata S., et al. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: evidence from a case-control study and meta-analysis. Neurosci. Lett. 2007, 415:108-112.
31. Narita M., Aoki K., Takagi M., Yajima Y., Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 2003, 119(3):767-775.
32. Neves-Pereira M., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol. Psychiatry 2005, 10(2):208-212.
33. Nikulina E.M., Johnston C.E., Wang J., Hammer R.P. Neurotrophins in the ventral tegmental area: role in social stress, mood disorders and drug abuse. Neuroscience 2014, 282C:122-138.
34. Numata S., Ueno S., Iga J., Yamauchi K., Hongwei S., Ohta K., et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci. Lett. 2006, 401:1-5.
35. Nurjono M., Lee J., Chong S.A. A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin. Psychopharmacol. Neurosci. 2012, 10(2):61-70.
36. Nyholt D.R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 2004, 74(4):765-769.
37. Pae C.U., Chiesa A., Porcelli S., Han C., Patkar A.A., Lee S.J., et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology 2012, 65(1):1-11.
38. Papiol S., Malzahn D., Kästner A., Sperling S., Begemann M., Stefansson H., et al. Dissociation of accumulated genetic risk and disease severity in patients with schizophrenia. Transl. Psychiatry 2011, 10.1038/tp.2011.43.
39. Phillips M.R., Zhang J., Shi Q., Song Z., Ding Z., Pang S., et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet 2009, 373:2041-2053.
40. Pillai A., Kale A., Joshi S., Naphade N., Raju M.S., Nasrallah H., et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int. J. Neuropsychopharmacol. 2010, 13(4):535-539.
41. Qian L., Zhao J., Shi Y., Zhao X., Feng G., Xu F., et al. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem. Biophys. Res. Commun. 2007, 353(3):738-743.
42. Rao J., Chiappelli J., Kochunov P., Regenold W.T., Rapoport S.I., Hong L.E. Is schizophrenia a neurodegenerative disease? Evidence from age-related decline of brain-derived neurotrophic factor in the brains of schizophrenia patients and matched nonpsychiatric controls. Neurodegener. Dis. 2015, 15(1):38-44.
43. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J. Biol. Psychiatry 2010, 11(2 Pt 2):251-255.
44. Rosa A., Cuesta M.J., Fatjó-Vilas M., Peralta V., Zarzuela A., Fañanás L. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2006, 141B:135-138.
45. Suchanek R., Owczarek A., Kowalski J. Association study between BDNF C-281A polymorphism and paranoid schizophrenia in Polish population. Mol. Neurosci. 2012, 46(1):217-222.
46. Terracciano A., Piras M.G., Lobina M., Mulas A., Meirelles O., Sutin A.R., et al. Genetics of serum BDNF: meta-analysis of the Val66Met and genome-wide association study. World J. Biol. Psychiatry 2013, 14(8):583-589.
47. Varnas K., Lawyer G., Jonsson E.G., Kulle B., Nesvag R., Hall H., et al. Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. Psychiatr. Genet. 2008, 18:177-183.
48. Watanabe Y., Nunokawa A., Someya T. Association of the BDNF C270T polymorphism with schizophrenia: updated meta-analysis. Psychiatry Clin. Neurosci. 2013, 67(2):123-125.
49. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33(8):1508-1512.
50. Yang Y.Q., Sun S., Yu Y.Q., Li W.J., Zhang X., Xiu M.H., et al. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neurosci. Lett. 2011, 502(1):37-40.
51. Yang X.X., Zhu A.N., Li F.X., Zhang Z.X., Li M. Neurogenic locus notch homolog protein 4 and brain-derived neurotrophic factor variants combined effect on schizophrenia susceptibility. Acta Neuropsychiatr. 2013, 25(6):356-360.
52. Yi Z., Zhang C., Wu Z., Hong W., Li Z., Fang Y., Yu S. Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Res. 2011, 1417:146-150.
53. Zhang X.Y., Zhang W.F., Zhou D.F., Chen da C., Xiu M.H., Wu H.R., et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol. Psychiatry 2012, 72(8):700-706.
54. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Luo X., Xu K., et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum. Genet. 2012, 131(7):1187-1195.
55. Zhao X., Huang Y., Chen K., Li D., Han C., Kan Q. The brain-derived neurotrophic factor Val66Met polymorphism is not associated with schizophrenia: an updated meta-analysis of 11,480 schizophrenia cases and 13,490 controls. Psychiatry Res. 2015, 225(1-2):217-220.
56. Zhou D.H., Yan Q.Z., Yan X.M., Li C.B., Fang H., Zheng Y.L., et al. The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(6):930-933.